DISC MEDICINE INC (IRON)

Company Profile

Disc Medicine, Inc. operates as a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2020-08-12. The firm is primarily engaged in discovering, developing, and commercializing treatments for patients who suffer from serious hematologic diseases. The company is building a portfolio of therapeutic candidates that focuses to address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin, which is for the treatment of erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP) and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD); MWTX-003 for the treatment of polycythemia vera (PV), and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, which is for the treatment of anemia associated with inflammatory diseases.

Company Info

DISC MEDICINE INC

321 Arsenal Street, Suite 101

Watertown MASSACHUSETTS

P: 16176749274

Employees: 46

Website: https://www.discmedicine.com/